Ensysce Biosciences, Inc. - Common Stock (NQ:ENSC)

0.4298 +0.0108 (+2.58%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ensysce Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Crude Oil Falls Over 3%; Philip Morris Earnings Top Views ↗

April 23, 2025

Via Benzinga

Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results ↗

April 23, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 23, 2025

Via Benzinga

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

April 23, 2025

Via ACCESS Newswire

Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled ↗

April 15, 2025

The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.

Via Stocktwits

Topics Government

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

March 10, 2025

Via ACCESS Newswire

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

February 05, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 15, 2025

Via Benzinga

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

April 15, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 10, 2025

Via Benzinga

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

March 31, 2025

Via ACCESS Newswire

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

January 22, 2025

Via ACCESS Newswire

Ensysce Biosciences Issues Annual Shareholder Letter

January 08, 2025

Via ACCESSWIRE

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

March 18, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 13, 2025

Via Benzinga

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

March 05, 2025

Via ACCESS Newswire

Ensysce Biosciences Regains Full Compliance with Nasdaq

December 23, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

December 10, 2024

Via ACCESSWIRE

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

December 04, 2024

Via ACCESSWIRE

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

November 26, 2024

Via ACCESSWIRE

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

November 12, 2024

Via ACCESSWIRE

Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

December 04, 2024

Via Benzinga

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

December 03, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 13, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 07, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

November 07, 2024

Via Benzinga

Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket ↗

November 07, 2024

Via Benzinga

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

November 07, 2024

Via ACCESSWIRE

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 31, 2024

Via Benzinga

Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket ↗

October 31, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

17 18 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.